CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 180 enrolled
Drug / intervention
d-cycloserine +1 moredrug
Likely dose
d-cycloserine 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00790868
NCT00790868Phase 2Completed
CompareCT.gov

Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder

Boston University Charles River Campus·interventional·Posted Nov 14, 2008·Updated Mar 7, 2018

In Brief

A Phase 2 clinical trial evaluating d-cycloserine and placebo for Panic Disorder. Completed, enrolled 180 participants across 4 sites.

Detailed Summary

This is a 5-year double blind, randomized, controlled, trial conducted at three treatment sites, aimed at showing the acute and longer-term effects of DCS augmentation of exposure-based CBT for panic disorder relative to placebo augmentation. By demonstrating that DCS can enhance the results of even a brief treatment strategy, the investigators are seeking to validate an approach that fits well with the practice limitations and applications of CBT in effectiveness studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPanic Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 14, 2008
Enrollment StartApr 1, 2008
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 17.6 years ago

Interventions

d-cycloserinedrug

50mg

placebodrug

50mg